Recursion Pharmaceuticals Inc (RXRX) - Total Assets
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) holds total assets worth $1.21 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Recursion Pharmaceuticals Inc - Total Assets Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see market value of Recursion Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Recursion Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Recursion Pharmaceuticals Inc's total assets of $1.21 Billion consist of 55.1% current assets and 44.9% non-current assets. Review Recursion Pharmaceuticals Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.4% |
| Accounts Receivable | $24.65 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $309.90 Million | 21.0% |
| Goodwill | $162.16 Million | 11.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See RXRX stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Recursion Pharmaceuticals Inc's current assets represent 55.1% of total assets in 2025, a decrease from 75.3% in 2019.
- Cash Position: Cash and equivalents constituted 50.4% of total assets in 2025, down from 68.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 21.0% of total assets.
Recursion Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Recursion Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Recursion Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.03 | 3.58 | 13.99 |
| Quick Ratio | 5.03 | 3.58 | 13.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $483.58 Million | $423.13 Million | $557.93 Million |
Recursion Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Recursion Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.13 |
| Latest Market Cap to Assets Ratio | 1.18 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | $1.47 Billion |
| Market Capitalization | $1.73 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Recursion Pharmaceuticals Inc's assets above their book value (1.18x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Recursion Pharmaceuticals Inc's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual total assets of Recursion Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.47 Billion | +1.76% |
| 2024-12-31 | $1.45 Billion | +121.60% |
| 2023-12-31 | $653.70 Million | -6.79% |
| 2022-12-31 | $701.29 Million | +14.90% |
| 2021-12-31 | $610.35 Million | +104.41% |
| 2020-12-31 | $298.58 Million | +194.37% |
| 2019-12-31 | $101.43 Million | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more